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Abstract To validate an established breast cancer inci-
dence model in an independent prospective data set. After
aligning time periods for follow-up, we restricted popula-
tions to comparable age ranges (47–74 years), and fol-
lowed them for incident invasive breast cancer (follow-up
1994–2008, Nurses’ Health Study [NHS]; and 1995–2009,
California Teachers Study [CTS]). We identified 2026
cases during 540,617 person years of follow-up in NHS,
and 1,400 cases during 288,111 person years in CTS. We
fit the Rosner–Colditz log-incidence model and the Gail
model using baseline data. We imputed future use of hor-
mones based on type and prior duration of use and other
covariates. We assessed performance using area under the
curve (AUC) and calibration methods. Participants in the
CTS had fewer children, were leaner, consumed more
alcohol, and were more frequent users of postmenopausal
hormones. Incidence rate ratios for breast cancer showed
significantly higher breast cancer in the CTS (IRR = 1.32,
95 % CI 1.24–1.42). Parameters for the log-incidence
model were comparable across the two cohorts. Overall,
the NHS model performed equally well when applied in the
CTS. In the NHS the AUC was 0.60 (s.e. 0.006) and
applying the NHS betas to the CTS the performance in the
independent data set (validation) was 0.586 (s.e. 0.009).
The Gail model gave values of 0.547 (s.e. 0.008), a sig-
nificant 4 % lower, p \ 0.0001. For women 47–69 the
AUC values for the log-incidence model are 0.608 in NHS
and 0.609 in CTS; and for Gail are 0.569 and 0.572. In both
cohorts, performance of both models dropped off in older
women 70–87, and later in follow-up (6–12 years). Cali-
bration showed good estimation against SEER with a non-
significant 4 % underestimate of overall breast cancer
incidence when applying the model in the CTS population
(p = 0.098). The Rosner–Colditz model performs consis-
tently well when applied in an independent data set. Per-
formance is stronger predicting incidence among women
47–69 and over a 5-year time interval. AUC values exceed
those for Gail by 3–5 % based on AUC when both are
applied to the independent validation data set. Models may
be further improved with addition of breast density or other
markers of risk beyond the current model.
Keywords Breast cancer  Prediction models 
Validation  Calibration  Methods
B. A. Rosner  S. E. Hankinson
Channing Division of Network Medicine, Department of
Medicine, Harvard Medical School, Boston, MA, USA
B. A. Rosner
Department of Biostatistics, Harvard School of Public Health,
Boston, MA, USA
G. A. Colditz (&)
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and
Washington University School of Medicine, 660 South Euclid
Avenue, Campus Box 8100, Saint Louis, MO 63110, USA
e-mail: colditzg@wustl.edu
S. E. Hankinson
Division of Biostatistics and Epidemiology, University of
Massachusetts, Amherst, MA, USA
S. E. Hankinson
Channing Division of Network Medicine, Department of
Medicine, Brigham and Women’s Hospital, Boston, MA, USA
J. Sullivan-Halley  J. V. Lacey Jr.  L. Bernstein
Division of Cancer Etiology, Department of Population
Sciences, Beckman Research Institute of the City of Hope,
Duarte, CA, USA
123
Breast Cancer Res Treat (2013) 142:187–202
DOI 10.1007/s10549-013-2719-3
Introduction
For over a decade since developing and expanding the
Rosner–Colditz model for breast cancer incidence [1, 2],
we have sought approaches to estimating performance in
an independent validation data set. Although we have
conducted internal validation using split sample approa-
ches [3], we have not previously used an independent data
set to assess performance. This has largely been due to the
need for data on age at each birth for women, an input to
spacing of births that directly relates to breast cancer risk in
early studies [4] and is confirmed in our model [5] and by
others [6]. The closer births are together, the more rapidly
breast tissue-aging decreases and the lower total risk
accumulates through premenopausal years [7]. In addition,
details on age at menopause and type of menopause as well
as type and duration of postmenopausal hormone therapy
(HT) are important risk factors.
Our approach then is to use an independent data set to
estimate performance following the principles outlined in
literature addressing validation and application of predic-
tion models in medicine [8, 9]. To date, no model of breast
cancer incidence has been implemented as part of routine
clinical care where risk estimates might guide level of
screening, genetic counseling, or chemoprevention.
As previously noted, the Rosner–Colditz model includes
a range of established reproductive factors, body mass
index (BMI), and alcohol intake in its basic form [2]. This
is one of a large number of breast cancer risk prediction
models. In a systematic review and meta-analysis, Meads
et al. [10] identified 17 breast cancer risk models with
differing sets of modifiable and non-modifiable risk factors,
with many omitting age at menopause, type of menopause,
and use of postmenopausal hormones, all factors strongly
related to future breast cancer risk. Only four models had
validation in potentially independent data sets. These
models included Gail [11] and also the Rosner–Colditz
model [1, 2, 12]. The performance of the Gail model
summarized as AUC in a previous validation within the
NHS data was 0.58, though both have not been compared
in a common independent data set.
Moons and others emphasize a sequence of model
development, validation, application, and assessment of
performance in application/clinical setting [8, 9]. To date,
we find no reports on the last aspect of breast cancer model
performance in routine clinical settings. Here we focus on
the conduct of validation in an independent data set.
We collaborated with California Teachers Study (CTS)
investigators to draw on an independent prospective data set
and assess the performance of the Rosner–Colditz model,
which was developed and refined in the Nurses’ Health Study
(NHS). We also compare model performance against the
Gail model when both are fit to the independent data set.
Methods
As noted above, a key issue in identifying an independent
prospective study with appropriate risk factor collection
included the need for details of age at each pregnancy, a
refinement of usual reporting of age at first birth and
number of births typical of epidemiologic studies. Details
on age and type of menopause were also important since
this is omitted from the Gail model despite a long record of
being established as a modifier of future breast cancer risk
[5, 13, 14]. Other key risk factors not included in the Gail
model are duration and type of postmenopausal HT used
[15], BMI [16], and alcohol intake [17]. These are all in the
Rosner–Colditz log-incidence model.
CTS This cohort contains the necessary data collected at
baseline in 1995 for the cohort. The CTS approach to
questionnaire follow-up, after 2 years, then after 3 more
years, then at varying intervals each updating some expo-
sures, together with case ascertainment ongoing annually
through the California tumor registry, meant we use
baseline data only. We limit the population to women who
were postmenopausal at baseline. To compare incidence
during common follow-up time periods we use the time
frame for CTS from baseline 1995 to 2009.
NHS This cohort of women followed from 1976 has
routinely updated information every 2 years on reproduc-
tive risk factors for breast cancer, family history of breast
cancer, use of postmenopausal hormones, and from 1980
onwards alcohol intake. The original Rosner–Colditz
model was developed in the broader NHS cohort [1, 2, 5].
For comparability with data available from the CTS, we
limit the population for this analysis to women who were
postmenopausal at baseline in 1994. Thus the correspond-
ing time available for the NHS is 1994–2008. In 1994,
NHS participants were 47–74. Hence, we limit the CTS
participants included in the analysis to a comparable age
range, excluding their older cohort members.
Model fitting issues
Limited only to baseline data from the CTS, we modified
the Rosner–Colditz model to omit updating. Because this
differs from our standard approach of updating exposure
information every 2 years [2], we estimate the impact of
this modification on overall performance.
Duration of current use of postmenopausal HT is signifi-
cantly related to incidence of breast cancer [2, 18], and to
type of menopause, age at menopause, and time since men-
opause. These factors are all importantly related to post-
menopausal breast cancer incidence. We, therefore, used
imputation methods to estimate future duration of use for
postmenopausal HT in the CTS [19]. We used a two-step
process to estimate use according to type of hormone used
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currently, and duration of use. We first fit a model to NHS
data to estimate the duration of hormone use from 1994 to the
return of the 2006 follow-up questionnaire for each type of
HT (estrogen, E, alone and estrogen plus a progestin, E&P).
Predictors included menopause type and time since meno-
pause, and duration of use of HT among current users (see
Tables 8 and 9). In addition to these characteristics of men-
opause, parity was positively related to ever use of E alone
but not E&P, and positively to duration of use of estrogen
alone, but inversely to duration of estrogen plus progestin.
BMI was inversely related to ever use of E and E&P, but was
unrelated to duration of use of either. Alcohol use was
inversely related to ever use of E alone and to ever use of
E&P, but not to duration of use of either formulation. We
developed this model separately for use of E alone and for use
of E&P. We then used this model with baseline CTS data to
impute future use by type and duration for participants,
taking the average of 5 imputations for each participant. (See
Tables 8 and 9 for the imputation models and Appendix 2 for
a summary of the imputation strategy.)
Time frame
To compare incidence of breast cancer in the two cohorts
over a common time frame, we identified common subsets
from the two cohorts. We use the CTS baseline in 1995 and
1994 as the start point for inclusion of NHS follow-up. We
then draw on the age range of the NHS participants to
define a comparable age range for CTS participants. Thus
we limit NHS follow-up data to the interval 1994–2008.
CTS data for the corresponding years are included with
follow-up from 1995 to 2009.
During follow-up of the NHS cohort from 1994 to 2008,
we identified 2,026 invasive breast cancer diagnoses
among postmenopausal women during 540,617 person
years. In the CTS, we identified 1,400 incident invasive
breast cancer diagnoses among postmenopausal women
during 288,111 person–years.
Description of the log-incidence model of breast cancer
We assume that the incidence of breast cancer at time t (It)
is proportional to the number of cell divisions accumulated
throughout life up to age t (i.e., It = kCt).








Thus, ki ¼ Ciþ1Ci ¼ the rate of increase in Ct from age i to
age i þ 1.
Log (kiÞ is assumed to be a linear function of risk factors
that are relevant at age i: The set of relevant risk factors
and their magnitude and/or direction may vary according to
the stage of reproductive life. We fit PROC NLIN of SAS
to estimate the parameters of the model with breast cancer
risk factors including (1) duration of premenopause, (2)
duration postmenopause, (3) type of menopause, natural or
surgical (4) parity, (5) age at each birth, (6) current, past
HRT use, (7) duration of HT use by type, (8) BMI, pre-
menopause : BMI1, (9) BMI, postmenopause : BMI2,
(10) height, (11) benign breast disease (BBD), (12) alcohol
intake, (13) family history of breast cancer.
We fit the base model using baseline variables and
imputed HT duration without updating exposures and
assessed covariates using the CTS comparing their mag-
nitude and direction to the variables in the NHS. We assess
the performance of the model from the NHS in the CTS by
fitting the NHS model and averaging five imputations of
HT use. We fit the Gail model [11] using the formula from
page 1880, with the caveat that in each cohort the number
of previous biopsies is scored 0 or 1 and the number of
relatives with family history is scored 0 or 1. We compare
the c-statistic for Gail versus Rosner–Colditz log-incidence
using the Wilcoxon rank sum test [20].
To assess calibration, we use the NHS model to esti-
mate relative risks for individual women in the CTS and
combine these with SEER data to estimate absolute risk.
We then group the CTS participants by decile of esti-
mated absolute risk and compare observed and expected
counts of incident breast cancers and test for trend using
Poisson regression approaches (for additional details, see
Appendix 1).
To assess calibration, we apply the NHS risk model to
the CTS population using imputed data for HRT use over
12 years. Suppose there are N subjects in the CTS popu-
lation who are followed for T person–years. We divide the
T person–years into L age strata and let Tl = number of
person–years in the lth age stratum. Based on the NHS risk
model, we compute the relative risk for the ith person at the
jth person–year given by RRij compared to a hypothetical
person at baseline risk where all covariate values are 0. Let
h1
*(l) be the age-specific incidence rate for the lth age group
from SEER 1995–2006. We use the methods of Gail (1989)
to combine the RRij from the NHS model with h1
*(l) to
estimate h1(l) = baseline incidence rate for the lth age
group of CTS. An estimate of the incidence rate for the ith





where dijl ¼ 1 if the ith subject is in age group l at the jth
person–year, = 0 otherwise.
The corresponding estimate of cumulative incidence for
the ith subject over ti person–years is given by
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Let Oi = 1 if the ith subject develops breast cancer over ti
person–years, = 0 otherwise.
If the NHS model is well calibrated in the CTS popu-
lation, then Oi should follow a Poisson distribution with
mean = Ei. To test this we let li ¼ EðOiÞ and consider the
Poisson regression model
ln lið Þ ¼ a þ lnðEiÞ
A test of the calibration of the model at the individual
level is
H0 : a ¼ 0 vs: H1 : a 6¼ 0
which we can perform using a Poisson regression model
with intercept only and offset given by lnðEiÞ.
We also can group the subjects into deciles by cumu-
lative incidence per year (or Ei ¼ Ei=ti) and compute the
observed (O(d)) and expected (E(d)) number of cases in the
dth decile and run a Poisson regression at the aggregate
level of the form:
ln lðdÞ
 
¼ a þ lnðEðdÞÞ
where lðdÞ ¼ EðOðdÞÞ:
The individual and aggregate Poisson regression models
are actually equivalent. The Poisson regression approach
should be a more sensitive model of goodness of fit than






which is more similar to a test of hetereogeneity than the
test for trend approach given by Poisson regression.
Finally, to combine inferences over several imputed data
sets, multiple imputation approaches are used to obtain an
overall test of calibration based on averaging estimates of a
over several imputations. More detail on the calibration
methodology is given in Table 8.
Results
Risk factor prevalence differences (Tables 1, 2)
Baseline data for the NHS and CTS are presented in
Table 1, for women 47–59 years at baseline, and Table 2,
for women 60–74 years of age. The mean age, age at
menarche, and age at menopause were comparable in the
cohorts as were the prevalence of biopsy confirmed BBD
and family history of breast cancer. The CTS included
more nulliparous women (25 %) versus 6 % in the NHS for
women 47–59 years, and 18 versus 6 % for women
60–74 years. CTS cohort members versus women in the
NHS had an average of 1 fewer births per woman; more
current postmenopausal hormone use (age 47–59 years: 70
vs. 56 %, age 60–74 years: 53 vs. 35 %) and longer
duration of use; leaner current BMI (age 47–59 years: 25.3
vs. 26.6, age 60–79 years: 25.3 vs. 26.1) and higher current
alcohol intake (age 47–59: 7.9 g/day vs. 5.0 g/day, 60–79:
8.2 g/day vs. 5.1 g/day).
Incidence rates (Table 3)
Age-specific and age-adjusted incidence rates show breast
cancer incidence rates are higher in the CTS for women
over age 60 years (Table 3). Across all ages, 47–87 years,
the age-adjusted incidence rate ratio shows that the CTS
has significantly higher incidence (age-adjusted IRR 1.32,
95 % CI 1.24–1.42).
Comparing parameter estimates in each cohort
(Table 4)
The modified model using only baseline data and imputed
HT duration of use was fit separately to the NHS and then
to the CTS cohort data to compare coefficients side by side
(see Table 4). We note a number of important similarities
across the two independent cohort studies supporting
favorable performance. The magnitude of the coefficient
for age at first birth (gynecologic age at first birth) is
comparable, being positive in both cohorts. The associated
birth index (a summary of total years from each birth to
minimum [age, or age at menopause], summed over all
births in parous women and = 0 for nulliparous women)
shows a strong inverse association of comparable magni-
tude in both cohorts (-0.0032 in NHS vs. -0.0026 in
CTS). Thus, for a typical woman with menarche at age 13,
menopause at 50, births at 20, 23, 26, 29, (giving a birth
index 102), this translates to a RR 0.72 for the NHS and
0.77 for the CTS. Terms for BBD and family history are
comparable as are the association for alcohol and for height
and BMI among women not taking HT (estrogen negative
time).
We also note some differences between the two cohorts.
The magnitude of the association for duration of E&P has a
larger magnitude in the CTS, b = 0.035 versus 0.015 in
NHS. The term for current use is weaker in the CTS, giving a
combined relative risk for a current user with 5 years of use
of e0.202? 5(0.035) = e0.377 = 1.46 compared to a never user
for the CTS and e0.368?5(0.015) = e0.443 = 1.56 for the NHS.
For current users with 10 years of use, the RRs are 1.74 for
the CTS and 1.68 for the NHS. Thus, the overall associations
for current users are comparable at longer durations of use.
The association for BMI is somewhat weaker during
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estrogen negative time (postmenopause, non-use of post-
menopausal hormones) in the CTS compared to the NHS
(0.00038 vs. 0.00195 per BMI unit per year).
Summary model performance in NHS and CTS cohorts
(Table 5)
We fit model coefficients from Table 4 to NHS and applied
the coefficients from NHS to CTS data for follow-up from
1995 to 2009 as an external validation of the NHS model
(see Table 5). The overall performance in the NHS was
0.597 for the full follow-up and 0.586 in CTS. For the first
5-year follow-up interval among women 47–69 years, the
risk prediction performance was comparable in both cohorts
(0.608 in NHS and 0.609 in CTS) supporting validity of the
model. We also observed that in NHS during the first 5-year
follow-up period, 1994–1999, performance was higher in
women 47–69 years (c = 0.608) than in those 70–87 years
(c = 0.587). For the second follow-up interval from 2000 to
2008 the model again performed better in younger women
c = 0.599 compared to older women c = 0.577, but in each
group performance was lower than in the first time interval.
This pattern of performance was also observed when the
Gail model was applied to the NHS cohort performance was
higher in younger women and in the first versus second
follow-up interval.
Applying the NHS log-incidence model to the CTS data,
a similar pattern emerged; the performance was better
during the first 5 years of follow-up in younger than older
women (c = 0.609 for 47–69 year old women vs. 0.564 for
70–87 year old women). During the later follow-up,
2001–2009, the performance was further reduced. The Gail
model applied to the CTS data also showed this pattern in
the first follow-up interval.
Table 1 Comparison of baseline risk factors between NHS and CTS, age 47–59
Variable NHS CTS
Mean ± SD Range N Mean ± SD Range N
Age 54.8 ± 3.1 47–59 18,308 54.0 ± 3.3 47–59 11,419
Age at menarche 12.4 ± 1.3 9–21 18,308 12.5 ± 1.4 10–17 11,419
Age at menopause 47.9 ± 5.1 21–59 18,308 48.0 ± 4.8 35–56 11,419
Type of menopause
Natural 13,910 (76 %) 8,393 (74 %)
Bilateral oophorectomy 4,398 (24 %) 3,026 (26 %)
Nulliparous (%) 1,075 (6 %) 2,858 (25 %)
Age at 1st birtha 24.6 ± 3.0 15–46 17,233 25.6 ± 4.6 14–46 8,561
Parity
0 1,075 (6 %) 2,858 (25 %)
1 1,355 (7 %) 1,695 (15 %)
2 6,016 (33 %) 4,094 (36 %)
C3 9,862 (53 %) 2,772 (24 %)
Mean 2.7 ± 1.4 0–15 18,308 1.7 ± 1.3 0–10 11,419
Birth index 58.0 ± 33.9 0–236 18,308 36.3 ± 32.6 0–316 11,419
Age at 1st birth–age at menarche 12.2 ± 3.3 1–32 17,233 13.1 ± 4.8 0–32 8,561
Current PMH use 10,232 (56 %) 7,975 (70 %)
Past PMH use 2,457 (13 %) 1,168 (10 %)
Duration E use (years) 1.4 ± 3.6 0–34.0 18,308 2.0 ± 4.1 0–20.0 11,419
Duration E&P use (years) 1.2 ± 2.1 0–14.0 18,308 2.1 ± 3.0 0–20.0 11,419
Current BMI (kg/m2) 26.6 ± 5.3 12.5–68.7 18,308 25.3 ± 5.3 16.2–60.6 11,419
BMI at age 18 (kg/m2) 21.3 ± 2.9 13.1–43.3 18,308 21.4 ± 3.4 14.5–53.3 11,419
Height 64.6 ± 2.4 48–79 18,308 64.8 ± 2.6 45–76 11,419
Alcohol (g/day) 5.0 ± 9.3 0–292.8 18,308 7.9 ± 9.6 0–112.8 11,419
Alcohol at age 18 (g/day) 3.2 ± 5.1 0–108.1 18,308 5.3 ± 8.2 0–157.2 11,419
Benign breast disease (%) (biopsy confirmed) 4,203 (23 %) 2,181 (19 %)
Family Hx breast cancer (%) 2,049 (11 %) 1,497 (13 %)
a Among parous women
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Comparing the Gail model to the log-incidence model in the
independent CTS data, the AUC for the Gail model perfor-
mance was 4 % lower overall (c = 0.547 vs. 0.586,
p\0.0001); during the first follow-up period for women
47–69 years (c = 0.572 vs. 0.609, difference in AUC = 0.037,
p = 0.008), and in women 70–87 years (c = 0.516 vs. 0.564,
difference in AUC = 0.048, p = 0.09). In the later follow-up
from 2001 to 2009 these differences persisted.
Comparison of c statistic for actual NHS data
versus the use of imputed values in that cohort
(Table 6)
To assess the drop off in model performance induced by
not updating exposure variables, we next fit the model to
NHS data using first imputed and then updated values for
HT duration (see Table 6). Fitting the model to NHS
updated data from 1994 through 2008 (right hand panel of
Table 6) we observe an AUC c statistic value of 0.616 (s.e.
0.006). If instead of using observed updated data, we
impute future duration of HT after menopause, the AUC
c statistic is reduced modestly to 0.600 (s.e. 0.006). When
assessing performance in the early follow-up from baseline
and later follow-up—again the actual data were compara-
ble to imputed data for the first 5 years, but showed
reduced performance in the 2000–2008 interval. For
example, for women 47–69, the AUC decreased from
0.641 with actual updated data to 0.595 using imputed data.
Calibration observed and expected counts in CTS
by decile of risk, predicted with NHS betas
Finally, we use five imputations to estimate the expected
number of cases of breast cancer according to the NHS
Table 2 Comparison of baseline risk factors between NHS and CTS, age 60–74
Variable NHS CTS Variable NHS CTS Variable
Mean ± SD Range Mean ± SD Range
Age 66.0 ± 3.8 60–74 27,434 66.1 ± 4.1 60–74 11,222
Age at menarche 12.7 ± 1.4 9–21 27,434 12.6 ± 1.4 10–17 11,222
Age at menopause 49.2 ± 4.8 20–66 27,434 49.8 ± 4.8 35–56 11,222
Type of menopause
Natural 21,838 (80 %) 9,097 (81 %)
Bilateral oophorectomy 5,596 (20 %) 2,125 (19 %)
Nulliparous (%) 1,744 (6 %) 2,012 (18 %)
Age at 1st birtha 25.7 ± 3.6 16–47 25,690 25.3 ± 4.2 14–46 9,210
Parity
0 1,744 (6 %) 2,012 (18 %)
1 1,879 (7 %) 1,147 (10 %)
2 6,281 (23 %) 3,037 (27 %)
C3 17,530 (64 %) 5,026 (45 %)
Mean 3.2 ± 1.8 0–16 27,434 2.3 ± 1.6 0–13 11,222
Birth index 64.8 ± 39.4 0–259 27,434 52.2 ± 40.6 0–321 11,222
Age at 1st birth–age at menarche 13.0 ± 3.8 1–35 25,690 12.6 ± 4.3 1–34 9,210
Current PMH use 9,474 (35 %) 5,942 (53 %)
Past PMH use 7,580 (28 %) 1,854 (17 %)
Duration E use (years) 2.4 ± 5.2 0–48.4 27,434 3.8 ± 6.5 0–20.0 11,222
Duration E&P use (years) 0.9 ± 2.1 0–14.0 27,434 3.2 ± 4.8 0–20.0 11,222
Current BMI (kg/m2) 26.1 ± 5.0 12.9–69.4 27,434 25.3 ± 4.8 16.0–60.4 11,222
BMI at age 18 (kg/m2) 21.3 ± 3.0 10.8–59.3 27,434 21.5 ± 3.1 15.0–48.4 11,222
Height 64.4 ± 2.4 39–79 27,434 64.4 ± 2.5 56–74 11,222
Alcohol (g/day) 5.1 ± 9.6 0–113.4 27,434 8.2 ± 10.4 0–130.8 11,222
Alcohol at age 18 (g/day) 2.5 ± 4.9 0–161.3 27,434 3.6 ± 6.4 0–116.1 11,222
Benign breast disease (%) (biopsy confirmed) 6,133 (22 %) 2,408 (21 %)
Family Hx breast cancer (%) 3,684 (13 %) 1,687 (15 %)
a Among parous women
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model stratifying the CTS participants by decile of risk. As
shown in Table 7, the observed count was slightly lower
than the predicted case count. Poisson regression across all
women allows estimation of the adjustment factor (a) =
-0.048, s.e. (a) = 0.027, p = 0.074. Overall the model fit
is not significantly different from SEER, O/E = 0.96 a 4 %
underestimate. Thus applying the NHS model with its rich
use of exposure across the life course for established breast
cancer risk factors, and accounting for the risk factor
profile of individual women in the CTS, we fully account
for breast cancer incidence in this independent population.
Discussion
We identified an independent large data set with 1,400
incident invasive breast cancer cases, that allowed evalu-
ation of a breast cancer incidence risk prediction models
using a common definition of incident invasive breast
cancer, over common time periods, and age groups. Age-
standardized breast cancer incidence in the CTS was sig-
nificantly higher than in NHS. Overall performance of the
Rosner–Colditz log-incidence model shows AUC consis-
tent with performance in the original NHS, supporting
external validity of the model. In the external validation
data set the model outperformed the Gail model by 3–5 %
for differing age groups and follow-up intervals based on
the AUC. Although adaptations had to be made using only
baseline data, this approach is comparable to using the tool
in clinical practice to predict risk and stratify women to
guide prevention interventions. Assessment of the lack of
updating but use of imputed duration of hormone use
among postmenopausal women showed modest attenuation
over a 5-year follow-up interval in the NHS. Calibration
against SEER showed good performance and close agree-
ment of predicted with observed incidence.
General issues on validating
Data availability on key reproductive variables including
age at first birth, age at each birth, menopause and type of
menopause, as well as history of biopsy confirmed BBD
and family history of breast cancer, height, weight, and
history of alcohol intake supported use of a common model
in comparable data that had been collected with similar
methods and would reflect approaches in clinical and epi-
demiologic practice. Because HT modifies risk of breast
cancer, imputing future use among current users was nec-
essary as the CTS does not update data every 2 years as
NHS does, and in clinical practice future use is unknown
but is important for risk prediction. Summary imputation
models are provided that may be of use for clinical appli-
cation in other settings where future use of hormones will
be estimated given past history ascertained at a clinic visit




Cases p_years Incidence rate (per 105
py)
Cases p_years Incidence rate (per 105
py)
IRR
47–49 7 1,764 396.8 2 2,511 79.6 0.20
50–54 74 23,452 315.5 48 18,792 255.4 0.81
55–59 275 66,427 414.0 177 43,889 403.3 0.97
60–64 434 109,802 395.3 298 60,673 491.2 1.24
65–69 523 127,301 410.8 328 61,539 533.0 1.30
70–74 460 117,401 391.8 274 50,987 537.4 1.37
75–79 217 68,627 316.2 197 32,853 599.6 1.90
80–87 36 25,844 139.3 76 16,867 450.6 3.23
Total 2,026 540,618 1,400 288,111
Crude 374.8 485.9 1.30
Age-adjusted 374.8 500.5 1.32
Crude IRR 1.30




95 % CI 1.24 1.42
Based on SEER data for white women, 1995–2006
Breast Cancer Res Treat (2013) 142:187–202 193
123
without any updating going forward. As seen in Tables 8
and 9 the imputation performed well in terms of ever use
(c statistic 0.87) and duration of use of estrogen alone and
estrogen plus progestin. Assessment indicates such impu-
tation is robust for 5 years, though predictive performance
may attenuate over longer follow-up or prediction time
intervals.
To fit the Gail model we used a common approach in
both cohorts and used family history positive without the
added detail of more than one relative. An extremely small
Table 4 Relationship between Breast Cancer Risk Factors and Breast Cancer, based on an average of 5 imputations of HT experience over 12
years
Variable Beta NHS California Teachers Study
2,026 cases 1,400 cases
540,618 person–years 288,111 person–years
s.e. p value Beta s.e. p value
Constant -7.420 0.352 \0.001 -8.048 0.322 \0.001
Duration of premenopause 0.044 0.009 \0.001 0.056 0.008 \0.001
Duration postmenopause
Natural menopause -0.009 0.005 0.069 0.017 0.006 0.002
Bilateral oophorectomy -0.015 0.006 0.013 0.012 0.008 0.15
Pregnancy history
Gynecologic age at 1st birtha 0.0089 0.0048 0.062 0.0055 0.0041 0.18
Birth index -0.0032 0.0007 \0.001 -0.0026 0.0008 0.001
BBD
BBD (yes vs. no) 0.237 0.588 0.69 0.314 0.834 0.71
BBD 9 age at menarche 0.021 0.024 0.37 0.078 0.039 0.046
BBD 9 duration of premenopause -0.002 0.011 0.84 -0.021 0.014 0.14
BBD 9 duration postmenopause -0.012 0.006 0.051 -0.018 0.009 0.044
HT use
Duration oral estrogen alone 0.021 0.007 \0.001 0.016 0.008 0.047
Duration oral estrogen plus progesterone 0.015 0.008 0.056 0.035 0.008 \0.001
Current use 0.368 0.093 \0.001 0.202 0.118 0.087
Past use 0.087 0.065 0.18 0.092 0.098 0.35
BMI (kg/m2)
Estrogen positiveb -0.00082 0.00024 \0.001 0.00000 0.00024 0.99
Estrogen negativec 0.00195 0.00042 \0.001 0.00038 0.00056 0.50
Height (in.)
Estrogen positive 0.00035 0.00032 0.27 0.00031 0.00020 0.12
Estrogen negative 0.00033 0.00098 0.74 -0.00030 0.00015 0.049
Alcohol intake (g)
Premenopause 0.00048 0.00014 \0.001 0.00042 0.00021 0.039
Postmenopause, while on HT 0.00004 0.0003 0.99 0.00015 0.00045 0.74
Postmenopause, while not on HT 0.00013 0.00019 0.48 -0.00032 0.00037 0.39
Family history of breast cancer 0.403 0.059 \0.001 0.346 0.069 \0.001
a Age at 1st birth minus age at menarche if parous, = 0 if nulliparous
b Either premenopause or postmenopause while on HT
c Postmenopause while not on HT
194 Breast Cancer Res Treat (2013) 142:187–202
123
fraction of all cohort members have more than one relative
with breast cancer, limiting the impact of this truncation of
data.
Review of evidence shows many models of breast cancer
incidence have been developed, but few are validated, and
perhaps even fewer evaluated for performance in clinical
Table 5 c Statistics by study, time period, and age group
Time period Age group Number of cases Log-incidence model Gail model Difference
AUC SE AUC SE AUC SE z value p value
NHS
1994–2008 47–87 2,026 0.597 0.007 0.562 0.006 0.034 0.007 4.857 1.191E-06
1994–1999 47–69 852 0.608 0.011 0.569 0.010 0.040 0.011 3.636 2.765E-04
1994–1999 70–87 301 0.587 0.016 0.555 0.017 0.032 0.017 1.882 0.060
2000–2008 47–69 461 0.599 0.013 0.572 0.013 0.026 0.012 2.167 0.030
2000–2008 70–87 412 0.577 0.016 0.543 0.014 0.034 0.016 2.125 0.034
California Teachers Study
1995–2009 47–87 1,400 0.586 0.009 0.547 0.008 0.040 0.009 4.444 8.812E-06
1995–2000 47–69 422 0.609 0.015 0.572 0.014 0.037 0.014 2.643 0.008
1995–2000 70–87 144 0.564 0.025 0.516 0.024 0.048 0.028 1.714 0.086
2001–2009 47–69 431 0.591 0.016 0.537 0.014 0.054 0.015 3.600 0.000
2001–2009 70–87 403 0.565 0.015 0.543 0.014 0.023 0.016 1.438 0.151
AUC area under the curve, SE standard error
Table 6 Comparison of c statistics with actual updated hormone therapy (HT) data versus imputed HT data by time period and age group, NHS
data 1994–2008
Time period Age groupa Imputation of follow-up HT datac Time period Age groupb Actual updated HT data
Number of cases AUC SE Number of cases AUC SE
1994–2008 47–87 2,026 0.600 0.006 1994–2008 47–87 2,026 0.616 0.006
1994–1999 47–69 852 0.620 0.010 1994–1999 47–69 851 0.618 0.010
1994–1999 70–87 301 0.585 0.016 1994–1999 70–87 302 0.590 0.016
2000–2008 47–69 461 0.595 0.013 2000–2008 47–69 457 0.641 0.013
2000–2008 70–87 412 0.575 0.015 2000–2008 70–87 416 0.626 0.014
AUC area under the curve, SE standard error
a Age group was defined by updating baseline (1994) age by 1 year for each succeeding year
b Age group was defined by using actual questionnaire age based on follow-up questionnaires
c Based on an average of five imputations of follow-up HT data
Table 7 Calibration of the NHS model in the California Teachers Study
Risk decile
1 2 3 4 5 6 7 8 9 10
Observed number of cases 71.6 94.6 111.6 119.6 126.0 129.6 152.0 150.4 195.6 248.8
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settings. This applies more broadly than just breast or other
cancer prediction—with limited validation and evaluation
of clinical impact of prediction models on disease out-
comes. For breast cancer, Meads [10] show the range of
variables included is substantial with many models not
including menopause, type of menopause, or use of post-
menopausal HT, or alcohol intake. Other than the Rosner–
Colditz model based on NHS data, only Boyle includes
alcohol [21], a known carcinogen for breast cancer [17], and
age at menopause is only included by Rosner–Colditz and
Tyrer [22]. Parity and BMI are more broadly included
across models [10]. The most complete of the 17 models
summarized by Meads is the Rosner–Colditz model with
external validity now established in this independent data
set. Several models were assessed for performance by Amir
et al. [23] in a UK population of 4,536 women attending a
‘‘family history and hereditary screening programme’’,
among whom 52 developed breast cancer. The Tyrer–
Table 8 Imputation models for estimating ever/never use of estrogen alone and duration of use of estrogen alone, NHS, 1995–2006 as a function
of baseline (1994) covariates
Variable Ever/never use of estrogen alone (n = 45,742)a ln(duration estrogen alone) (n = 9,145)b
Beta SE p value Beta SE p value
Constant -3.078 0.212 0.762 0.105
Duration of premenopause -0.002 0.005 0.68 -0.004 0.003 0.15
Duration postmenopause
Natural menopause -0.045 0.004 \0.001 -0.020 0.002 \0.001
Bilateral oophorectomy 0.011 0.004 0.005 -0.007 0.002 0.002
Pregnancy history
Gynecologic age at 1st birthc 0.0033 0.0035 0.35 -0.0022 0.0019 0.25
Birth index 0.0031 0.0005 \0.001 0.00052 0.00027 0.049
BBD
BBD (yes vs. no) 0.863 0.371 0.020 0.213 0.181 0.24
BBD 9 age at menarche -0.035 0.017 0.032 -0.0001 0.0085 0.99
BBD 9 duration of premenopause -0.011 0.007 0.10 -0.0032 0.0032 0.32
BBD 9 duration postmenopause -0.007 0.005 0.16 -0.0080 0.0025 0.001
HT use
Duration oral estrogen alone 0.235 0.005 \0.001 0.0282 0.0017 \0.001
Duration oral estrogen ? progesterone -0.041 0.007 \0.001 -0.0027 0.0041 0.52
Current use 1.978 0.053 \0.001 0.993 0.037 \0.001
Past use 0.580 0.059 \0.001 0.275 0.041 \0.001
BMI (kg/m2)
Estrogen positived 0.00035 0.00015 0.015 -0.00007 0.00007 0.34
Estrogen negativee -0.00081 0.00045 0.074 -0.00002 0.00027 0.94
Height (in.)
Estrogen positived 0.00003 0.00019 0.88 -0.00015 0.00009 0.10
Estrogen negativee -0.00024 0.00090 0.79 0.00113 0.00052 0.030
Alcohol intake (g)
Premenopause -0.00012 0.00010 0.23 -0.00006 0.00006 0.26
Postmenopause, while on HT -0.00102 0.00023 \0.001 0.00009 0.00009 0.29
Postmenopause, while not on HT 0.00073 0.00018 \0.001 -0.00013 0.00012 0.29
Family history of breast cancer 0.148 0.046 0.30 -0.041 0.025 0.099
c statistic 0.871 –
R2 – 0.271
a Over 12 years (1995–2006)
b Among women with duration of estrogen alone [0 over 12 years (1995–2006)
c Age at 1st birth minus age at menarche if parous, = 0 if nulliparous
d Either premenopause or postmenopause while on HT
e Postmenopause while not on HT
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Cuzick model [22] had the best performance based on
c statistic, though the O/E performance was at the level of
0.8 for this model compared to 0.9 for Gail [23]. While
Amir and Tyrer–Cuzick have been evaluated in high-risk
populations where they are likely to perform better, such a
comparison in the general population has not been reported.
For CHD on the other hand, Van Dieren et al. [24]
review evidence on model development and evaluation—
45 prediction models reported in the literature, 12 specific
for patients with diabetes; 31 % validated in independent
population of diabetics, and only one evaluated in clinic for
its effect on patient management.
Table 9 Imputation models for estimating ever/never use of estrogen plus progestin (E&P) and duration of use of E&P, NHS, 1995–2006 as a
function of baseline (1994) covariates
Variable Ever/never use of E&P (n = 45,742)a ln(duration E&P) (n = 11,516)b
Beta SE p value Beta SE p value
Constant 0.405 0.212 1.291 0.115
Duration of premenopause -0.041 0.005 \0.001 -0.0061 0.0030 0.038
Duration postmenopause
Natural menopause -0.077 0.003 \0.001 -0.018 0.002 \0.001
Bilateral oophorectomy -0.309 0.008 \0.001 -0.043 0.004 \0.001
Pregnancy history
Gynecologic age at 1st birthc 0.0010 0.0031 0.74 0.0012 0.0016 0.48
Birth index 0.0000 0.0004 0.94 -0.0008 0.0002 \0.001
BBD
BBD (yes vs. no) -0.336 0.399 0.40 -0.344 0.211 0.10
BBD 9 age at menarche -0.003 0.016 0.84 0.0100 0.0080 0.21
BBD 9 duration of premenopause 0.009 0.008 0.24 0.0049 0.0041 0.23
BBD 9 duration postmenopause 0.001 0.004 0.84 -0.0016 0.0025 0.52
HT use
Duration oral estrogen alone -0.048 0.007 \0.001 0.012 0.004 0.001
Duration oral estrogen plus progesterone 0.414 0.008 \0.001 0.062 0.003 \0.001
Current use 1.356 0.037 \0.001 0.471 0.023 \0.001
Past use 0.453 0.041 \0.001 -0.179 0.028 \0.001
Body mass index (kg/m2)
Estrogen positived -0.00032 0.00014 0.027 -0.00003 0.00008 0.65
Estrogen negativee -0.00088 0.00042 0.036 -0.00011 0.00028 0.69
Height (in.)
Estrogen positived -0.00026 0.00019 0.19 0.00005 0.00009 0.58
Estrogen negativee 0.00031 0.00084 0.71 -0.00079 0.00051 0.12
Alcohol intake (g)
Premenopause 0.00010 0.00009 0.29 -0.00001 0.00005 0.88
Postmenopause, while on HT -0.00121 0.00032 \0.001 -0.00001 0.00014 0.96
Postmenopause, while not on HT 0.00016 0.00017 0.37 -0.00023 0.00012 0.055
Family history of breast cancer -0.23 0.044 \0.001 -0.035 0.024 0.14
c statistic 0.870 –
R2 – 0.207
a Over 12 years (1995–2006)
b Among women with duration of E&P [ 0 over 12 years (1995–2006)
c Age at 1st birth minus age at menarche if parous, = 0 if nulliparous
d Either premenopause or postmenopause while on HT
e Postmenopause while not on HT
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Calibration
While age-standardized incidence rates differ between
NHS and CTS the coefficients for risk factors when fitted
to the Rosner–Colditz breast cancer incidence model are
quite comparable and evaluation of predicted incidence in
the calibration analysis shows no significant deviation from
SEER incidence, with O/E of 0.96. The range of incidence
expected in the SEER calibration study reveals approxi-
mately fourfold difference in expected values between
lowest and highest decile. This is a non-trivial spread in
risk across deciles and is evaluated by the Poisson
regression to assess trend in difference between O and E
over deciles of risk. The observed lower incidence in NHS
may reflect cohort follow-up procedures that do not fully
capture incident breast cancers as efficiently as the sur-
veillance through the state tumor registry in California, a
state with historically low out migration. As all women
should have access to Medicare after age 65, differential
screening and access to care should not be an issue when
comparing these two cohorts.
Future issues
Future applications in routine clinical settings will add
further modeling issues. For example, as approximately
one-third of women report hysterectomy in the United
States and because age at menopause is an important risk
factor in our model, we will need to impute estimated age
at menopause among women with hysterectomy before
menopause. We have previously derived an algorithm for
use in this setting [25]. Other missing data will also need to
be addressed, likely using NHANES data as has been
implemented in clinical applications of a risk model for
progression of age-related macular degeneration using
demographic, genetic, environmental, and ocular factors
[26]. Other clinical application data come from the United
Kingdom where Evans and colleagues have collected
breast risk data in a routine breast screening setting, and
report evaluation of the Tyrer and Cuzick breast risk model
at the level of distributions of 10-year risk and also assess
SNPs in a subset of women. Approximately 34 % of
women attending breast screening enrolled and risk esti-
mates were returned to those with 10-year risk above 8 %
(107 women). Performance assessment of the tool is
ongoing in this routine mammography setting [27]. The
breast cancer surveillance consortium generated a risk
prediction model among more than 1 million women
undergoing mammography [28]. They began with age,
race, ethnicity, and breast density (measure with BI-RADS)
and adjusted estimates of family history and history of
breast biopsy. The model was developed in 60 % of the
population and validated in the remaining 40 %, and is
well calibrated, though it does not include any reproductive
or lifestyle predictors of breast cancer. While these two
examples indicate that risk factors and prediction can be
incorporated into mammography services, issues of miss-
ing data and real time estimation of risk have yet to be
addressed, and the impact of risk presentation on clinical
decision making and outcomes of care has not been
evaluated.
Conclusion
Through validation in an independent data set, we have
shown that the Rosner–Colditz model performs consis-
tently when applied in that independent setting. Perfor-
mance is stronger predicting incidence among women
47–69 years and over a 5-year time interval. AUC values
are significantly higher than the Gail model in the inde-
pendent validation data set, and may be further improved
with addition of breast density or other markers of risk
beyond the current model. Further refinement may be
needed to handle missing data in routine clinical settings.
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Appendix 1: Calibration procedure—CTS validation
study
We follow the general calibration procedure of Gail (1989).
Procedure for the mth imputation
1. We wish to apply the NHS risk model to the CTS
population, where the incidence model is of the form:
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2. Suppose there are N subjects in the CTS population
who are followed collectively for T person–years.




ti ¼ T ;
and that mij = age of the ith subject at the jth person–
year.
4. We divide the T person–years into L age strata and let







q ¼ 1 if a1  mij\ a2;
¼ 2 if a2  mij\a3;
. . .
¼ l if al  mij\alþ1;
. . .
¼ L if aL  mij\aLþ1:
In this case, L = 8 and the age groups are defined by
45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79,
80–87.
5. We define a person as being at baseline risk in the lth
age stratum if x = 0.
6. We define covariate values for the ith person in the







i ¼ 1; . . .; N; j ¼ 1; . . .; ti:
7. Let
Yl ¼ observed number of cases in age group l;
l ¼ 1; . . .; L;
Oij ¼ 1 if the ith subject becomes a case in the
jth person  year;¼ 0 otherwise:
dijl ¼ 1 if al  mij\al þ 1;¼ 0 otherwise;









; l ¼ 1; . . .; L:
9. Let
h1ðlÞ ¼ age-specific incidence rate from SEER
19952006; l ¼ 1; . . .; L:
10. Let
h1 lð Þ ¼ h1 lð ÞFl;
¼ baseline incidence rate in the
lth age stratum of CTS; l ¼ 1; . . . ; L:
11. An estimate of the incidence rate for the ith subject in




h1 lð ÞdijlRRij; i ¼ 1; . . .; N; j ¼ 1; . . .; ti
12. An estimate of the cumulative incidence for the ith
subject over ti person–years is given by:





; i ¼ 1; . . .; N
13. Let
Oi ¼ 1 if the ith subject is a case over
ti person-years;
¼ 0 if the ith subject is a control over
ti person-years; i ¼ 1; . . .; N:
14. Compute
Ei ¼ Ei=ti ¼ cumulative incidence per person
year for the ith subject; i ¼ 1; . . .; N and rank
subjects by decile of Ei :
15. Let
kid ¼1 if subject i is in the dth decile of Ei ;





Oikid ¼ observed number of cases in the




Eikid ¼ expected number of cases in the
dth decile of Ei
17. Poisson regression at the aggregate level
Run Poisson regression of O(d) using ln(E(d)) as the
offset based on the model:
ln ldð Þ ¼ a þ ln E dð Þ
 
; where ld ¼ E O dð Þ
 
or equivalently ld ¼ expðaÞE dð Þ
Note in the above model, a = 0 implies that
ld = E
(d).
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18. Poisson regression at the individual level
Run Poisson regression of Oi using ln(Ei) as the offset
based on the model:
ln lið Þ ¼ a þ ln Eið Þ;
or
Oi ¼ exp að ÞEi;
where
li ¼ E Oið Þ:
Note a = 0 implies that li = Ei. Also, the models in
steps 17 and 18 are equivalent because O(d) is a sum







Eikid ¼ exp að ÞE dð Þ:
19. If we average SEER incidence rates for white women
from 1995 to 2000 and 2000 to 2006, we obtain:
Overall inference over m imputations
20. For step 16, let




m ¼ observed count, expected count and
person–years for the dth risk decile in the mth
imputation. The overall estimates of O dð Þ, E dð Þ and
T dð Þ are given by:
O dð Þ ¼
XM
m¼1









T dð Þm =M:
For steps 17 and 18, we obtain the estimate:
a^ðmÞ for the mth imputation and associated estimate





with associated variance given by:




þ M þ 1ð Þ=M½ 
XM
m¼1




za^ ¼ a^= var a^ð Þ½ 1=2 N 0; 1ð Þ under H0 that a ¼ 0;
p-value ¼ 2  1  Ujzaj½ :
Appendix 2: Imputation strategy for ever use and duration



















where pi1 = Prob(duration estrogen alone [ 0,
1994-2006) for the ith NHS woman, i = 1,…, 45742,
pi2 = Prob(duration E&P[0, 1994–2006) for the ith
NHS woman, I = 1,…, 45742, xik = kth breast cancer
risk factor for the ith subject, I = 1,…, 45742, k =
1,…, K and let p^i1; p^i2 be the corresponding estimated
probabilities obtained by substituting the estimated
parameters a^1; a^2 and b^k1; b^k2, k = 1, …, K for the
true parameters in Eq. 1.
2. Let yi1 ¼ lnðduration of use of estrogen alone for the
ith NHS woman, where ;yi1 [0yi2
yi2 ¼ ln duration of use of E &P for the
ith NHS woman, where yi2 [0:
3. (a) Let










zi1 ¼ ln yi1ð Þ; zi2 ¼ ln yi2ð Þ; ei1 N 0; r2i1
 









45–49 253.3 64.2 1
50–54 336.8 269.2 47
55–59 417.0 407.1 173
60–64 494.2 493.2 297
65–69 538.8 534.6 328
70–74 579.3 540.4 268
75–79 592.6 582.0 166
80–87 517.4 476.1 55
We used the SEER incidence rates in column 2 as our estimates of
h1ðlÞ, l ¼ 1; . . .; L
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be linear regressions of zi1 and zi2 on ~xi, respectively.
(b) Let








be the corresponding predicted values of zi1 and zi2,
respectively.
(c) Let r^21; r^
2
2 be the estimated residual variances
corresponding to zi1 and zi2, in Eq. 2,
respectively.
4. Let Ui1, Ui2 be U(0,1) random variables and let ui1,
ui2 be the realization of these random variables
generated using the RANUNI function of SAS.
Let Vi1, Vi2 be corresponding N(0,1) random vari-
ables and let vi1, vi2 be the realization of these
random variables generated using the RANNOR
function of SAS.
5. Let y^i1; y^i2 = imputed estimate of duration of estro-
gen alone and duration of E&P, respectively, for the
ith NHS woman.
(a) If p^i1\ui1, then di1 ¼ 1; else di1 ¼ 0:
(b) If p^i2\ui2, then di2 ¼ 1; else di2 ¼ 0:
(c) Let
w^i1 ¼ z^i1 þ r^1vi1;
w^i2 ¼ z^i2 þ r^2vi2:
(d) (i) If di1 ¼ di2 ¼ 0; then y^i1 ¼ y^i2 ¼ 0;
(ii) If di1 ¼ 1 and di2 ¼ 0; then y^i1 ¼
min exp w^i1ð Þ; 12½ ; y^i2 ¼ 0;
(iii) If di1 ¼ 0 and di2 ¼ 1; then y^i1 ¼ 0; y^i2 ¼
min exp w^i2ð Þ; 12½ ;
(iv) If di1 ¼ 1 and di2 ¼ 1; and w^i1 [ w^i2; then
y^i1 ¼ min exp w^i1ð Þ; 12½ ; y^i2 ¼ 0;
(v) If di1 ¼ 1 and di2 ¼ 1; and w^i1\w^i2; then
y^i1 ¼ 0; y^i2 ¼ min exp w^i2ð Þ; 12½ :
6. (a) Based on steps 1–5, we estimate duration of e-
strogen alone and duration of E&P for all NHS
women and fit the log-incidence model descri-
bed in step 1, assuming that duration of HT is
continuous starting in 1994 and ceases after d-
uration y^i1 or y^i2, respectively.
(b) We repeat (a) five times and obtain five separate
estimates of a and b, respectively. Let a^m; b^k;m
be the estimates of and bk for the mth impu-
tation, k = 1,…, K.



























7. A similar strategy as in step 6 is used to obtain
multiple imputation estimates of AUC based on
imputed data, where Var^ðAUCÞ is obtained using the
methods in Rosner and Glynn [20].
8. For imputation with the CTS data, we use the NHS
prediction equations in (1) and (2) and proceed as in
steps 5 and 6 to obtain overall estimates of a and b
for CTS as given in Table 4.
9. Estimates of AUC are obtained for CTS based on the
coefficients a^ and b^ obtained from NHS data in step
6. The AUC estimates were obtained for five imputed
CTS datasets and combined using the methods in step
6.
10. Similarly, calibration of the NHS model based on the
coefficients a^ and b^ in step 6 were applied to five
imputed CTS datasets. Separate estimates of observed
counts, expected counts and Poisson regression
parameters were obtained for each imputed CTS
dataset and combined using multiple imputation
methods described in Appendix 1.
References
1. Rosner B, Colditz GA (1996) Nurses’ health study: log-incidence
mathematical model of breast cancer incidence. J Natl Cancer
Inst 88(6):359–364
2. Colditz G, Rosner B (2000) Cumulative risk of breast cancer to
age 70 years according to risk factor status: data from the Nurses’
Health Study. Am J Epidemiol 152(10):950–964
3. Colditz G, Rosner B, Chen WY, Holmes M, Hankinson SE
(2004) Risk factors for breast cancer: according to estrogen and
progesterone receptor status. J Natl Cancer Inst 96:218–228
4. Trichopoulos D, Hsieh CC, MacMahon B et al (1983) Age at any
birth and breast cancer risk. Int J Cancer 31(6):701–704
5. Rosner B, Colditz GA, Willett WC (1994) Reproductive risk
factors in a prospective study of breast cancer: the Nurses’ Health
Study. Am J Epidemiol 139(8):819–835
6. Lambe M, Hsieh C-c, Trichopoulos D, Ekbom A, Pavia A, Ad-
ami H-O (1994) Transient increase in risk of breast cancer after
giving birth. N Engl J Med 331:5–9
7. Colditz GA, Rosner BA (2006) What can be learnt from models
of incidence rates? Breast Cancer Res 8(3):208
8. Moons KG, Kengne AP, Grobbee DE et al (2012) Risk prediction
models: II. External validation, model updating, and impact
assessment. Heart 98(9):691–698
9. Moons KG, Kengne AP, Woodward M et al (2012) Risk pre-
diction models: I. Development, internal validation, and assessing
the incremental value of a new (bio)marker. Heart 98(9):683–690
Breast Cancer Res Treat (2013) 142:187–202 201
123
10. Meads C, Ahmed I, Riley RD (2012) A systematic review of
breast cancer incidence risk prediction models with meta-analysis
of their performance. Breast Cancer Res Treat 132(2):365–377
11. Gail MH, Brinton LA, Byar DP et al (1989) Projecting individ-
ualized probabilities of developing breast cancer for white
females who are being examined annually. J Natl Cancer Inst
81:1879–1886
12. Rosner B, Colditz GA, Iglehart JD, Hankinson SE (2008) Risk
prediction models with incomplete data with application to pre-
diction of estrogen receptor-positive breast cancer: prospective
data from the Nurses’ Health Study. Breast Cancer Res 10(4):R55
13. Lilienfeld AM (1956) The relationship of cancer of the female
breast to artificial menopause and marital status. Cancer
9:927–934
14. Trichopoulos D, MacMahon B, Cole P (1972) Menopause and
breast cancer risk. J Natl Cancer Inst 48(3):605–613
15. International Agency for Research on Cancer (2008) Monograph
on the evaluation of carcinogenic risk to humans: combined
estrogen/progestogen contraceptives and combined estrogen/
progestogen menopausal therapy. Combined estrogen-progesto-
gen contraceptives and combined estrogen-progestogen meno-
pausal therapy, vol 91. IARC Press, Lyon.
16. International Agency for Research on Cancer (2002) Weight
control and physical activity, vol 6. International Agency for
Research on Cancer, Lyon
17. IARC Working Group on the Evaluation of Carcinogenic Risks to
Humans (2007) Alcohol consumption and ethyl carbamate.
International Agency for Research on Cancer, Lyon (Distributed
by WHO Press, 2010)
18. Colditz GA, Hankinson SE, Hunter DJ et al (1995) The use of
estrogens and progestins and the risk of breast cancer in post-
menopausal women. N Engl J Med 332:1589–1593
19. Bernstein L, Allen M, Anton-Culver H et al (2002) High breast
cancer incidence rates among California teachers: results from
the California Teachers Study (United States). Cancer Causes
Control 13:625–635
20. Rosner B, Glynn RJ (2009) Power and sample size estimation for
the Wilcoxon rank sum test with application to comparisons of C
statistics from alternative prediction models. Biometrics
65(1):188–197
21. Boyle P, Mezzetti M, La Vecchia C, Franceschi S, Decarli A,
Robertson C (2004) Contribution of three components to indi-
vidual cancer risk predicting breast cancer risk in Italy. Eur J
Cancer Prev 13(3):183–191
22. Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction
model incorporating familial and personal risk factors. Stat Med
23(7):1111–1130
23. Amir E, Evans DG, Shenton A et al (2003) Evaluation of breast
cancer risk assessment packages in the family history evaluation
and screening programme. J Med Genet 40(11):807–814
24. van Dieren S, Beulens JW, Kengne AP et al (2012) Prediction
models for the risk of cardiovascular disease in patients with type
2 diabetes: a systematic review. Heart 98(5):360–369
25. Rosner B, Colditz GA (2011) Age at menopause: imputing age at
menopause for women with a hysterectomy with application to
risk of postmenopausal breast cancer. Ann Epidemiol
21(6):450–460
26. Seddon JM, Reynolds R, Yu Y, Daly MJ, Rosner B (2011) Risk
models for progression to advanced age-related macular degen-
eration using demographic, environmental, genetic, and ocular
factors. Ophthalmology 118(11):2203–2211
27. Evans DG, Warwick J, Astley SM et al (2012) Assessing indi-
vidual breast cancer risk within the U.K. National Health Service
Breast Screening Program: a new paradigm for cancer preven-
tion. Cancer Prev Res 5(7):943–951
28. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow
WE, Kerlikowske K (2008) Using clinical factors and mammo-
graphic breast density to estimate breast cancer risk: development
and validation of a new predictive model. Ann Intern Med
148(5):337–347
202 Breast Cancer Res Treat (2013) 142:187–202
123
